Artal Group S.A. Global Blood Therapeutics, Inc. Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$45.7 - $81.86 $16 Million - $28.7 Million	-350,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$45.35 - $57.91 $15.9 Million - $20.3 Million	350,000 New	350,000 $17 Million
Q3 2018 Nov 09, 2018	SELL	$38.0 - $51.1 $7.6 Million - $10.2 Million	-200,000 Closed	0 $0
Q1 2018 May 10, 2018	SELL	$39.6 - $65.9 $5.94 Million - $9.89 Million	-150,000 Reduced 42.86%	200,000 $9.66 Million
Q4 2017 Feb 09, 2018	BUY	$29.7 - $45.7 $1.49 Million - $2.29 Million	50,000 Added 16.67%	350,000 $13.8 Million
Q3 2017 Nov 08, 2017	BUY	$25.1 - $31.05 $7.53 Million - $9.32 Million	300,000	300,000 $9.32 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.